

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

BSE Limited 1 st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u>	National Stock Exchange of India Limited Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u>
Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan	Kind Attn.: Famroze Pochara Asst. Vice President
Date: January 17, 2017	
Re.: Press Release	

Dear Sir / Madam,

We enclose herewith a copy of press release dated January 17, 2017, titled Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on Livalo® (pitavastatin calcium) tablets.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **Cadila Healthcare Limited**



Upen H. Shah
Company Secretary



Encl.: As above

Zydus announces settlement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. on Livalo® (pitavastatin calcium) tablets

Ahmedabad, January 17, 2017

Cadila Healthcare Limited, a global pharmaceuticals company, and its subsidiary Zydus Pharmaceuticals (USA) Inc., a leading generic pharmaceutical company in the United States, today announced that they have finalized an agreement with Kowa Company, Ltd., Kowa Pharmaceuticals America, Inc. and Nissan Chemical Industries, Ltd. to settle all outstanding patent litigation related to Livalo® (pitavastatin calcium) tablets.

Under the terms of the agreement, Kowa and Nissan grants Zydus a license to market Zydus' generic version of Livalo® beginning on May 2, 2023, or earlier under certain circumstances. Other terms of the settlement were not disclosed.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 19,500 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
